Nevus Count, Pigmentary Characteristics, and Melanoma-specific Mortality among Norwegian Women with Melanoma >1.0 mm Thick.


Journal

Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310

Informations de publication

Date de publication:
04 Apr 2023
Historique:
received: 29 07 2022
accepted: 24 01 2023
medline: 6 4 2023
entrez: 4 4 2023
pubmed: 5 4 2023
Statut: epublish

Résumé

Little is known about if and how nevi and pigmentation are associated with melanoma-specific mortality. However, increased melanoma awareness in people with lighter pigmentation and many nevi may result in earlier diagnosis of thinner less-lethal tumors. The aim of this study was to investigate associations between nevus count (asymmetrical > 5 mm and small symmetrical), pigmentary characteristics (hair colour, eye colour, skin colour, freckling, pigmentary score), and melanoma-specific mortality in subjects with melanomas > 1 mm. Data from the Norwegian Women and Cancer cohort, established in 1991, with complete follow-up of melanoma patients until 2018 through the Cancer Registry of Norway, were used to estimate hazard ratios with 95% confidence intervals for the associations between nevus count, pigmentary characteristics, and melanoma-specific mortality, stratified by tumor thickness using Cox regression. Estimated hazard ratios consistently indicated a higher risk of melanoma death for those with darker vs lighter pigmentary characteristics in patients with tumors > 1.0-2.0 mm and > 2.0 mm thick (e.g. pigmentary score hazard ratio 1.25, 95% confidence interval (0.74-2.13)). Among women with melanomas > 1.0 mm thick, lighter pigmentation and asymmetrical nevi may be associated with lower melanoma-specific mortality, suggesting that factors that increase the risk of melanoma may also be associated with decreased risk of death from melanoma.

Identifiants

pubmed: 37014267
doi: 10.2340/actadv.v103.4403
pmc: PMC10108620
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

adv4403

Références

Br J Dermatol. 2007 May;156(5):938-44
pubmed: 17381454
JAMA. 2016 Jan 5;315(1):68-76
pubmed: 26746459
Eur J Cancer. 2008 Jun;44(9):1275-81
pubmed: 18406602
Melanoma Res. 2020 Apr;30(2):179-184
pubmed: 31574530
Oncogene. 2014 May 8;33(19):2413-22
pubmed: 23728340
G Ital Dermatol Venereol. 2010 Feb;145(1):37-45
pubmed: 20197744
Int J Cancer. 2015 Dec 15;137(12):3006-7
pubmed: 26095813
Int J Epidemiol. 2008 Feb;37(1):36-41
pubmed: 17644530
J Am Acad Dermatol. 2019 May;80(5):1284-1291
pubmed: 30639880
Eur J Cancer. 2013 Aug;49(12):2705-16
pubmed: 23583439
Arch Dermatol. 2006 Dec;142(12):1551-8
pubmed: 17178980
Pigment Cell Melanoma Res. 2012 May;25(3):384-94
pubmed: 22325793
Cancer. 2004 Nov 1;101(9):2067-78
pubmed: 15372475
J Natl Cancer Inst. 2003 Oct 15;95(20):1530-8
pubmed: 14559875
Cancer Treat Res. 2016;167:17-49
pubmed: 26601858
Sci Rep. 2018 Jul 19;8(1):10947
pubmed: 30026606
Dermatology. 2017;233(1):1-15
pubmed: 28463841
J Natl Cancer Inst. 2005 Feb 2;97(3):195-9
pubmed: 15687362
J Am Acad Dermatol. 2018 Jul;79(1):118-125.e1
pubmed: 29580861
Melanoma Res. 2019 Aug;29(4):445-446
pubmed: 31246726
JAMA Dermatol. 2021 Dec 01;157(12):1425-1436
pubmed: 34730781
JAMA Oncol. 2022 May 1;8(5):755-759
pubmed: 35323844
Am J Hum Genet. 2010 Jul 9;87(1):6-16
pubmed: 20602913
Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):971-8
pubmed: 10566551
JAMA Dermatol. 2015 Sep;151(9):982-90
pubmed: 26039788
Melanoma Res. 2008 Feb;18(1):1-9
pubmed: 18227701
Br J Dermatol. 2020 Jan;182(1):138-146
pubmed: 31016712
Acta Derm Venereol. 2021 Apr 29;101(4):adv00446
pubmed: 33880571
Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):217-224
pubmed: 30341099
J Am Acad Dermatol. 2005 Jan;52(1):40-7
pubmed: 15627079
Int J Cancer. 2018 Dec 15;143(12):3097-3105
pubmed: 29987865
J Transl Med. 2022 Sep 5;20(1):403
pubmed: 36064556
FASEB J. 2010 Oct;24(10):3850-60
pubmed: 20519635
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Pigment Cell Melanoma Res. 2019 Jul;32(4):593-600
pubmed: 30706692
Int J Cancer. 2016 Sep 15;139(6):1217-22
pubmed: 27101944
Epidemiology. 2017 May;28(3):379-386
pubmed: 28244888
Melanoma Res. 2016 Aug;26(4):401-8
pubmed: 26990272
Int J Cancer. 2015 Oct 1;137(7):1691-8
pubmed: 25809795

Auteurs

Ashley Ahimbisibwe (A)

Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway. ashley.ahimbisibwe@medisin.uio.no.

Morten Valberg (M)

Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.

Adele C Green (AC)

Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia; Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.

Reza Ghiasvand (R)

Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway; Department of Research, Cancer Registry of Norway, Oslo, Norway.

Corina S Rueegg (CS)

Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.

Raju Rimal (R)

Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway.

Elisabete Weiderpass (E)

International Agency for Research on Cancer, Lyon, France. Director@iarc.fr.

Torkjel M Sandanger (TM)

Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.

Trude E Robsahm (TE)

Department of Research, Cancer Registry of Norway, Oslo, Norway.

Marit B Veierød (MB)

Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH